Practice
Open Access
Cardiorenal syndrome
Wen Qing Wendy Ye, Mohammad Azfar Qureshi and Bourne Auguste
CMAJ September 05, 2023 195 (34) E1154; DOI: https://doi.org/10.1503/cmaj.230226
Wen Qing Wendy Ye
Division of Nephrology (Ye, Qureshi, Auguste), Department of Medicine, University of Toronto; Division of Nephrology (Qureshi, Auguste), Sunnybrook Health Sciences Centre, Toronto, Ont.
MD MScMohammad Azfar Qureshi
Division of Nephrology (Ye, Qureshi, Auguste), Department of Medicine, University of Toronto; Division of Nephrology (Qureshi, Auguste), Sunnybrook Health Sciences Centre, Toronto, Ont.
MBBS MScBourne Auguste
Division of Nephrology (Ye, Qureshi, Auguste), Department of Medicine, University of Toronto; Division of Nephrology (Qureshi, Auguste), Sunnybrook Health Sciences Centre, Toronto, Ont.
MD MScIn this issue
Article extras
Article tools
Cardiorenal syndrome
Wen Qing Wendy Ye, Mohammad Azfar Qureshi, Bourne Auguste
CMAJ Sep 2023, 195 (34) E1154; DOI: 10.1503/cmaj.230226
Jump to section
- Article
- Cardiorenal syndrome is a bidirectional pathophysiological interaction between the heart and kidneys1
- It is associated with increased mortality among patients with heart failure2
- Patients with cardiorenal syndrome should be treated with angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)1
- Sodium–glucose cotransporter-2 (SGLT2) inhibitors should be added to ACE inhibitors or ARBs for renal and cardiovascular protection1,4
- Patients with cardiorenal syndrome benefit from guideline-directed medical therapy5
- Footnotes
- References
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.